Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106) Meeting Abstract
| Authors: | Ma, C. X.; Suman, V.; Leitch, A. M.; Sanati, S.; Vij, K.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O.; Guenther, J.; Caudle, A.; Crouch, E.; Maluf, H.; Tiersten, A.; Mita, M.; Razaq, W.; Hieken, T. J.; Wang, Y.; Dockter, T.; Zujewski, J. A.; Weiss, A.; Hunt, K.; Hudis, C.; Winer, E. P.; Ellis, M. J.; Carey, L. A.; Partridge, A. H. |
| Abstract Title: | Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106) |
| Meeting Title: | 43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 81 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Dec 8-11 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-02-01 |
| Language: | English |
| ACCESSION: | WOS:000618737700027 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS20-GS4-05 |
| Notes: | Meeting Abstract: GS4-05 -- This symposium was held virtually due to COVID-19 -- Source: Wos |
